The U.S. approved lenacapavir, a twice-yearly HIV prevention shot, marking a potential global breakthrough. Clinical trials showed it nearly eliminated new infections in high-risk groups, surpassing daily pills. However, access concerns exist due to U.S. healthcare cuts and reduced foreign aid. While the shot's list price is comparable to other PrEP options, affordability remains a challenge, particularly in middle-income countries. Gilead aims to supply 2 million people in low-income countries with the drug at no profit. Experts emphasize the need for widespread access to realize the shot's full potential in curbing the HIV pandemic.

Prepared by Olivia Bennett and reviewed by editorial team.